{"id":"NCT01974323","sponsor":"Almirall, S.A.","briefTitle":"Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris","officialTitle":"A Safety and Efficacy Study to Compare Dapsone Dermal Gel With Vehicle Control in Patients With Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2014-10","completion":"2014-10","firstPosted":"2013-11-01","resultsPosted":"2017-02-06","lastUpdate":"2018-10-09"},"enrollment":2238,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"Dapsone Gel","otherNames":[]},{"type":"DRUG","name":"Dapsone Gel Vehicle","otherNames":[]}],"arms":[{"label":"Dapsone Gel","type":"EXPERIMENTAL"},{"label":"Dapsone Gel Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.","primaryOutcome":{"measure":"Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)","timeFrame":"Week 12","effectByArm":[{"arm":"Dapsone Gel","deltaMin":29.8,"sd":null},{"arm":"Dapsone Gel Vehicle","deltaMin":20.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":3,"countries":["United States","Canada"]},"refs":{"pmids":["30500141","30500140","30500139","27847545"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":1117},"commonTop":[]}}